Menadione slows prostate cancer in mice in early animal study
A study in mice reports that menadione, a precursor of vitamin K, slowed prostate cancer by interfering with the survival processes of cancer cells. The results come from animal research, not trials in people.
Source: Menadione slows prostate cancer in mice in early animal study (scitechdaily.com). Summary written with AI from the source and reviewed by rules; read the original.
What the research shows
The study in mice looked at the effect of menadione, a precursor of vitamin K, on prostate cancer. According to the source, the substance slowed the disease in the animals by interfering with the processes that allow cancer cells to survive. The results come from animal research, not from trials in people.
Findings in animals are an early step in scientific research. Many substances that work in mice do not produce the same effect in the human body, and safety must also be assessed in people. This result should therefore be read as a lead for future investigation, not as a guide to treatment.
What it means
The result suggests that menadione may affect the survival of prostate cancer cells in mice. It is not yet known whether this approach would work in people, or what its effects and risks would be in humans.
How to read it with care
This result does not replace a medical consultation. Anyone considering a change in diet, supplements or treatment should talk to a doctor or another qualified health professional.